UCB (OTCPK:UCBJ.Y) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

UCBJ.Y Overzicht aandelen

UCB SA, een biofarmaceutisch bedrijf, ontwikkelt wereldwijd producten en oplossingen voor mensen met neurologische en immunologische ziekten.

Over het bedrijf

UCBJ.Y fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	4/6
Prestaties in het verleden	1/6
Financiële gezondheid	4/6
Dividenden	3/6

Beloningen

Verhandeld tegen 62.8% onder onze schatting van de reële waarde

De winst zal naar verwachting met 34.36% per jaar groeien

Risicoanalyse

Winstmarges (4.4%) zijn lager dan vorig jaar (6.5%)

UCB SA Concurrenten

Royalty Pharma

NasdaqGS:RPRX

US$16.6b

Zoetis

NYSE:ZTS

US$87.6b

Jazz Pharmaceuticals

NasdaqGS:JAZZ

US$7.1b

Organon

NYSE:OGN

US$4.5b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor UCB
Historische aandelenkoersen
Huidige aandelenkoers	€94.27
52 Week Hoogtepunt	€95.81
52 Week Laag	€34.85
Bèta	0.36
11 maand verandering	3.62%
3 maanden verandering	20.32%
1 Jaar Verandering	146.91%
33 jaar verandering	59.05%
5 jaar verandering	148.08%
Verandering sinds IPO	459.47%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	UCBJ.Y	US Pharmaceuticals	US Markt
7D	0.9%	0.2%	0.8%
1Y	146.9%	23.5%	38.4%

Rendement versus industrie: UCBJ.Y overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 23.1 % opleverde.

Rendement versus markt: UCBJ.Y overtrof de US markt, die het afgelopen jaar een rendement opleverde van 34.1 %.

Prijsvolatiliteit

Is UCBJ.Y's price volatile compared to industry and market?
UCBJ.Y volatility
UCBJ.Y Average Weekly Movement	3.7%
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.0%

Stabiele aandelenkoers: UCBJ.Y heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van UCBJ.Y is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1925	9,000	Jean-Christophe Tellier	www.ucb.com

UCB SA, een biofarmaceutisch bedrijf, ontwikkelt wereldwijd producten en oplossingen voor mensen met neurologische en immunologische ziekten. De belangrijkste producten van het bedrijf zijn Cimzia voor inflammatoire TNF-gemedieerde ziekten, evenals ankyloserende spondylitis, axiale spondyloartritis, de ziekte van Crohn, niet-radiografische axiale spondyloartritis, plaque psoriasis, psoriatische artritis en reumatoïde artritis; Vimpat, Keppra en Briviact voor epilepsie; Neupro voor de ziekte van Parkinson en het rustelozebenensyndroom; Nayzilam, een neusspray als reddingsbehandeling voor epilepsieaanvalclusters; en Zyrtec en Xyzal voor allergieën. Het bedrijf biedt ook Evenity voor de behandeling van osteoporose bij postmenopauzale vrouwen; Bimzelx voor de behandeling van plaque psoriasis, psoriatische artritis en axiale spondyloartritis; en Fintepla voor de behandeling van het Dravetsyndroom.

UCB SA Samenvatting

Hoe verhouden de winst en inkomsten van UCB zich tot de beurswaarde?
UCBJ.Y fundamentele statistieken
Marktkapitalisatie	US$35.74b
Inkomsten(TTM)	US$260.73m
Inkomsten(TTM)	US$5.93b

137.1x

Koers/Winstverhouding

6.0x

P/S-verhouding

Is UCBJ.Y overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
UCBJ.Y resultatenrekening (TTM)
Inkomsten	€5.45b
Kosten van inkomsten	€1.76b
Brutowinst	€3.70b
Overige uitgaven	€3.46b
Inkomsten	€240.00m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Feb 27, 2025

Winst per aandeel (EPS)	1.27
Brutomarge	67.80%
Nettowinstmarge	4.40%
Schuld/Eigen Vermogen Verhouding	31.8%

Hoe presteerde UCBJ.Y op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.8%

Huidig dividendrendement

108%

Uitbetalingsratio

UCBJ.Y Overzicht aandelen

Beloningen

Risicoanalyse

UCB SA Concurrenten

NasdaqGS:RPRX

US$16.6b

NYSE:ZTS

US$87.6b

NasdaqGS:JAZZ

US$7.1b

NYSE:OGN

US$4.5b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Recent updates

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs

UCB Announces Changes on Board of Directors

UCB SA to Report First Half, 2021 Results on Jul 29, 2021

doc.ai and UCB Teams Up to Develop Breakthrough Artificial Intelligence Models to Advance Care

UCB and Stanford Medicine Establish Multi-Year Collaboration

UCB Announces U.S. Food and Drug Administration Approval of VIMPAT

UCB SA (ENXTBR:UCB) agreed to acquire Handl Therapeutics from Gemma Frisius Fonds NV.

UCB Announces New Data on Its TNF Inhibitor

Bimekizumab Phase 3 Data Shows Superior Skin Clearance over Humira® in Moderate-To-Severe Psoriasis Patients

UCB Announces That the FDA and EMA Have Accepted the Biologics License Application (BLA) and Marketing Authorization Application (MAA), Respectively, for Bimekizumab for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

UCB SA to Report Fiscal Year 2020 Results on Feb 25, 2021

UCB SA (ENXTBR:UCB) completed the acquisition of Ra Pharmaceuticals, Inc. (NasdaqGM:RARX) from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and RA Capital Healthcare Fund, L.P managed by Ra Capital Management, LLC and others.

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

UCB SA Samenvatting

137.1x

6.0x

Inkomsten en omzet